Research programme: anti-cancer ligand proteins - Enchira

Drug Profile

Research programme: anti-cancer ligand proteins - Enchira

Alternative Names: ACL™ proteins; Anti-cancer ligand proteins research programme - Enchira; Receptor tyrosine kinase inhibitors research programme - Enchira

Latest Information Update: 13 Feb 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enchira Biotechnology Corporation [CEASED]
  • Class
  • Mechanism of Action Epidermal growth factor receptor antagonists; Epidermal growth factor stimulants; Insulin-like growth factor I inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 13 Feb 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 01 Jul 2002 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top